Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00690430 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 186
- Enrollment target
NCT00690430 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 186 participants.
The verdict
NCT00690430, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 186 participants
- Enrollment target
Study Summary
The purpose of this randomized, multicenter, Phase III study was to compare the efficacy of paseriotide LAR and octreotide LAR in patients whose disease-related symptoms are inadequately controlled by currently available somatostatin analogues.
Interventions
- DRUG Pasireotide
- DRUG Octreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2008-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00690430
The ClinicalTrials.gov registry entry for NCT00690430 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pasireotide is the first listed.
NCT00690430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00690430 about?
NCT00690430 is a clinical study titled "Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease". The purpose of this randomized, multicenter, Phase III study was to compare the efficacy of paseriotide LAR and octreotide LAR in patients whose disease-related symptoms are inadequately controlled by currently available somatostatin analogues.
What is the current status of trial NCT00690430?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 186 participants. The study started on 2008-04. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00690430?
The interventions under investigation include: Pasireotide (DRUG), Octreotide (DRUG).
Who is sponsoring clinical trial NCT00690430?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.